# The association between cannabis use and brain reward anticipation: a 12-month longitudinal study > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-brain-reward-processing-12-month-study/ > **Published:** 2026-04-24T02:34:16-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:13:18-04:00 > **Clinical Summary:** Explore cannabis brain reward processing and its effects on motivation in a 12-month neuroimaging study revealing key insights. --- ✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchNeurologyTHC[Mental Health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/) Clinical Summary # Clinical Summary This longitudinal neuroimaging study examined how [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) affects brain reward processing over 12 months, finding alterations in ventral striatal activation during reward anticipation in regular users compared to controls. The research demonstrates that chronic cannabis exposure may modulate dopaminergic reward circuitry, potentially contributing to motivational changes and cannabis dependence risk that clinicians observe in their patients. These neurobiological findings provide mechanistic insight into why some individuals develop problematic cannabis use patterns and may explain motivational symptoms patients report during sustained use. The study’s longitudinal design strengthens evidence that cannabis-related brain changes are not merely correlational but associated with patterns of ongoing use. Clinicians should counsel patients about cannabis effects on motivation and reward processing, particularly adolescents and young adults whose reward systems are still developing, and remain alert for motivational decline in regular users presenting with depressive symptoms or functional impairment. Dr. Caplan’s Take “What this neuroimaging data shows us is that regular cannabis use blunts the brain’s reward circuitry in measurable ways, and while we don’t yet know if this change is permanent or reversible after cessation, it’s a finding I share directly with patients who are concerned about motivation or anhedonia, because it gives us a concrete biological mechanism to work with rather than just subjective complaints.” Clinical Perspective This neuroimaging study demonstrating altered reward anticipation in cannabis users over a 12-month period adds to growing evidence that regular cannabis use may have meaningful effects on mesocortical reward circuitry, particularly in developing brains. However, clinicians should interpret these findings cautiously, as cross-sectional associations between cannabis use and brain function cannot definitively establish causation, and reverse causality remains plausible—individuals with baseline differences in reward processing may self-select into cannabis use. The clinical relevance is further complicated by variability in cannabis potency, frequency of use, age of initiation, and individual genetic predisposition, all of which likely modulate neurobiological effects but are difficult to control for in observational research. Despite these methodological limitations, the study provides useful objective data that clinicians can reference when counseling patients, particularly adolescents and young adults, about the potential neurobiological consequences of regular cannabis 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+The+association+between+%3Cb%3Ecannabis%3C%2Fb%3E+use+and+brain+reward+anticipation%3A+a+12-month+...+-+Nature+%40drcaplan&url=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41386-026-02377-3)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41386-026-02377-3)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+The+association+between+%3Cb%3Ecannabis%3C%2Fb%3E+use+and+brain+reward+anticipation%3A+a+12-month+...+-+Nature+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41386-026-02377-3)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Frequent social media use linked to cannabis use in adolescents – Medical Republic](https://cedclinic.com/adolescent-cannabis-use-social-media-risk/) - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - Teenage Cannabis Use Linked to 52% Higher Schizophrenia Risk – Neuroscience News 📰 Source: [https://www.nature.com/articles/s41386-026-02377-3](https://www.nature.com/articles/s41386-026-02377-3) Further Reading Cannabis Policy WireCED Regulatory Digest, Since Last Digest, 1 items Research Digest[Research Digest: 10 Recent Studies – April 22, 2026](https://cedclinic.com/recent-cannabinoid-clinical-research-april-2026/) Evidence Watch[Regional (in)Consistency and Comparability of Cannabis Laboratory Testing: A Statistical Exploration of Total Yeast and Mold.](https://cedclinic.com/cannabis-laboratory-testing-variability-safety/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Study highlights stroke risk linked to recreational drugs, including among young users](https://cedclinic.com/cannabis-stroke-risk-young-users-study-highlights/) This study explores stroke risks associated with recreational drug use, providing context for cannabis-related neurological effects. [Read More](https://cedclinic.com/cannabis-stroke-risk-young-users-study-highlights/) [Cannabis intoxication broadly impairs multiple memory types, new study shows – PsyPost](https://cedclinic.com/cannabis-working-memory-study-broad-cognitive-impairment/) New research reveals how cannabis intoxication affects various memory functions, complementing findings on brain reward processing. [Learn More](https://cedclinic.com/cannabis-working-memory-study-broad-cognitive-impairment/) What Doctors Want You to Know About [Cannabis and Health](https://cedclinic.com/gateway-drug-myth/) – The New York Times A comprehensive overview of cannabis and health from medical experts, useful for understanding clinical perspectives on cannabis brain effects. Explore Article ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).